 |
인쇄하기
취소
|
KFDA approved clinical studies for Sewon Cellontech's Ostem.
Sewon Cellontech announced on Dec. 28 that the KFDA approved the clinical study for Ostem, a cell therapy by differentiating adult stem cells into osteoblasts to treat bone necrotic disease.
The clinical study may be led by Prof. Kim Jeong-man, an orthopedic surgeon of Kangnam St. Mary hospital starting from Jan. 2006.
Osem has no any rejecting or adverse reactions as it is a cell therapy...
The clinical study may be led by Prof. Kim Jeong-man, an orthopedic surgeon of Kangnam St. Mary hospital starting from Jan. 2006.
Osem has no any rejecting or adverse reactions as it is a cell therapy...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.